› Forums › General Melanoma Community › ASCO review….new treatment options enrolling start us off
- This topic has 3 replies, 3 voices, and was last updated 6 years, 5 months ago by
lkb.
- Post
-
- June 24, 2019 at 12:39 am
Though I have put it off, I have embarked on my now annual review of ASCO reports. They are the most important solely per my perspective, reference links to prior reports and background info when I have it, and include ‘my take’ (in red) as is my usual. The first post is up and covers the fairly limited “NEW” stuff that came out in this year’s meeting. Specifically, it addresses currently recruiting trials offering NKTR-214 with nivo, IMO-2125 (a TLR agonist) with ipi, TIM-3, lifileucel used in TIL, and a biotherapeutic agent, taken orally with pembro. Three reports address the microbiome craze, including that last as well as flora in mice and antibiotic use in real live ratties.Here’s the link if you are interested: https://chaoticallypreciselifeloveandmelanoma.blogspot.com/2019/06/new-stuff-treatment-options-and-current.html
More reports on other topics to come in the next several days. Remember, despite the storm ~ there is beauty still. Wishing you all my best. Celeste
Viewing 2 reply threads
- Replies
-
-
- June 24, 2019 at 9:24 am
Thank you Celeste for such a concise and thorough review on the new treatments including your view. Calculated trial and error hoping for more success and finally a cure. I am interested to see that gut biome appears to play a significant role in the spread as well as treatment outcomes of many different cancers and illnesses. Obviously, our diet has a lot to do with this whether we like it or not. I hope that the new research makes more significant strides for us all in the very near future.
Thank you!
Melanie
-
Viewing 2 reply threads
- You must be logged in to reply to this topic.